A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

Inclusion Criteria: 1. Patient with advanced or metastatic solid tumors 2. Patients have an ECOG performance status of 0 to 1 3. Patients with a life expectancy of at least 3 months \[Tolerability confirmation part\] 4. Patients who are refractory or intolerant to standard therapy or for whom no standard therapy is available \[Expansion part\] 5. Patients who are refractory or intolerant to standard therapy, or for whom no standard therapy is available, or for whom monotherapy with intravenous nivolumab is indicated according to the package insert Exclusion Criteria: 1. Patients with a complication or history of severe hypersensitivity to any antibody product 2. Patients with severe complication